Theodore Alan Huizenga - Sep 1, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
SVP, Chief Accounting Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Sep 1, 2023
Transactions value $
-$36,032
Form type
4
Date filed
9/6/2023, 05:50 PM
Previous filing
May 10, 2023
Next filing
Sep 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale -$32.7K -883 -3.57% $37.04 23.9K Sep 1, 2023 Direct F1
transaction RARE Common Stock Sale -$3.33K -87 -0.36% $38.23 23.8K Sep 1, 2023 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this row of the Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F2 Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F3 The total amount of securities beneficially owned by the Reporting Person reflected in Table 1, Column 5 of this Form 4 reflects the correction of a typographical error in a previously filed Form 4 filed on April 18, 2023 ("April 2023 Form 4"). The corrected total amount of securities beneficially owned by the Reporting Person in Table 1, Column 5 of the April 2023 Form 4 is 21,520. The corrected total amount of securities beneficially owned by the Reported Person in Table 1, Column 5 of the Form 4 filed on behalf of the Reporting Person on May 10, 2023 is 24,747.
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.